Media Articles Related to Ovace Plus Shampoo (Sulfacetamide)
Source: MedicineNet Seborrhea Specialty [2016.08.22]
Title: Contact Dermatitis
Category: Diseases and Conditions
Created: 3/28/2013 12:00:00 AM
Last Editorial Review: 8/22/2016 12:00:00 AM
Eczema (Atopic Dermatitis) Causes, Symptoms, Treatment
Source: MedicineNet tacrolimus ointment Specialty [2016.05.24]
Title: Eczema (Atopic Dermatitis) Causes, Symptoms, Treatment
Created: 3/26/2012 12:00:00 AM
Last Editorial Review: 5/24/2016 12:00:00 AM
Source: MedicineNet Seborrhea Specialty [2016.03.18]
Title: Seborrheic Dermatitis
Category: Diseases and Conditions
Created: 3/16/2012 12:00:00 AM
Last Editorial Review: 3/18/2016 12:00:00 AM
Source: MedicineNet betamethasone dipropionate Specialty [2015.10.09]
Title: Atopic Dermatitis
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 10/9/2015 12:00:00 AM
Career advice for young allergy patients
Source: Allergy News From Medical News Today [2016.09.02]
Approximately one-third of apprentices in Germany are at elevated risk of occupational asthma, allergies, and dermatitis. In this edition of Deutsches Ă„rzteblatt International, Katja Radon et al.
Published Studies Related to Ovace Plus Shampoo (Sulfacetamide)
The multifunctionality of 10% sodium sulfacetamide, 5% sulfur emollient foam in the treatment of inflammatory facial dermatoses. [2010.03]
Prior to 1962, some of the most versatile drugs in dermatology were approved by the U.S...
Sulfacetamide loaded Eudragit(R) RL100 nanosuspension with potential for ocular delivery. 
PURPOSE: Polymeric nanosuspension was prepared from an inert polymer resin (Eudragit(R) RL100) with the aim of improving the availability of sulfacetamide at the intraocular level to combat bacterial infections... CONCLUSION: The results indicate that the formulation of sulfacetamide in Eudragit(R) RL100 nanosuspension could be utilized as potential delivery system for treating ocular bacterial infections.
Interaction of topical sulfacetamide and topical dapsone with benzoyl peroxide. [2009.09]
CONCLUSIONS: Knowledge of the chemical reaction between benzoyl peroxide and sulfacetamide and dapsone will help minimize the occurrence of this interaction on our patients' skin.
Bioadhesive sulfacetamide sodium microspheres: evaluation of their effectiveness in the treatment of bacterial keratitis caused by Staphylococcus aureus and Pseudomonas aeruginosa in a rabbit model. [2009.08]
The aim of this study was to prepare bioadhesive sulfacetamide sodium (SA) microspheres to increase their residence time on the ocular surface and to enhance their treatment efficacy on ocular keratitis. Microspheres were fabricated by spray drying method using mixture of polymers such as pectin, polycarbophil and hydroxypropylmethyl cellulose (HPMC) at different ratios...
Treatment of papulopustular rosacea with sodium sulfacetamide 10%/sulfur 5% emollient foam. [2009.03]
Acne rosacea is a chronic cutaneous disorder affecting as many as 14 million Americans.The high patient satisfaction ratings for SSSE foam suggest that the product may improve long-term compliance rates, with the potential to yield more favorable clinical outcomes.
Clinical Trials Related to Ovace Plus Shampoo (Sulfacetamide)
Effects of Hyperbaric Oxygen Therapy on Surgical Wound Healing [Enrolling by invitation]
The aim of this study is to test the effect of Hyperbaric Oxygen Therapy) HBOT (100% oxygen;
2. 0 ATA; 90 minute total exposure) and compare against a hyperbaric sham treatment (HBST)
(patient's breathing room air; 2. 0 ATA; 90 minute exposure) in reducing edema and
ecchymosis. HBOT will be applied as a single pre-operative and a single post-operative
treatment for patients undergoing eyelid surgery. Briefly, patients will be exposed to HBOT
2-4 hours prior to undergoing surgery, 2-4 hours post-surgery and healing will be assessed
at day 3, 10, 21, 30 & 90 days after surgery. Edema and ecchymosis will be assessed in a
time series to determine the extent that HBOT reduces these clinical signs. The primary
null hypothesis to test will be that no differences in scores will exist between treatment
and control at day 3, 10 & 21 post-surgery. A secondary null hypothesis to test is the time
required to change a score will be no different between the two groups.
HBOT=hyperbaric oxygen therapy; HBST=hyperbaric sham treatment
Patients Response to Early Switch To Oral:Osteomyelitis Study [Not yet recruiting]
Based on the current literature, investigators hypothesize that patients with osteomyelitis
who are treated with the standard approach of intravenous antibiotics for the full duration
of therapy will have the same clinical outcomes as patients treated with the experimental
approach of intravenous antibiotics with early switch to oral antibiotics.
The primary objective of this study is to compare patients with osteomyelitis treated with
the standard approach of intravenous antibiotics for the full duration of therapy versus
patients treated with intravenous antibiotics with an early switch to oral antibiotics in
relation to clinical outcomes at 12 months after discontinuation of antibiotic therapy.
Secondary objectives of the study include the evaluation of adverse events related to the
use of antibiotics as well as the cost of care evaluated from the hospital perspective.
Intraductal Meibomian Gland Probing Trial [Active, not recruiting]
In this research study, the investigators are looking at the effects of Meibomian Gland
Probing (MGP) versus a sham (fake) procedure in patients with refractory MGD who have
already tried traditional management with no success in resolving their clinical signs (as
seen by their ophthalmologist) or their symptoms.
The investigators are also evaluating the effects of using two (2) post-procedural
medication treatments: Blephamide or GenTeal PM Night-Time to determine if treatment after
the MGP procedure has an effect on its outcome.
The Effect of Sodium Thiosulfate Eardrops on Hearing Loss in Patients Who Receive Cisplatin Therapy [Terminated]
This is a pilot, randomized, self-controlled study of the effects of intratympanic sodium
thiosulfate (STS) on the degree of hearing loss in patients receiving cisplatin therapy.
Sodium thiosulfate is an inactive ingredient contained in sulfacetamide ophthalmic solution
which is used routinely as an otic solution delivered to the middle ear space.
The hypothesis of this study is that local administration of sodium thiosulfate (STS) will
result in improved hearing compared to ears not receiving the study drug in patients
receiving systemic cisplatin therapy.
ORCA - Oracea® for Rosacea: A Community-based Assessment [Completed]
The objective of this study is to assess the effectiveness, safety, subject satisfaction and
quality of life with Oracea® when used as monotherapy or as add-on therapy to existing
topical regimens for the treatment of rosacea.